These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17696799)

  • 1. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
    Pfützner A; Weber MM; Forst T
    Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A; Forst T
    Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
    Pfützner A; Schneider CA; Forst T
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
    Zinn A; Felson S; Fisher E; Schwartzbard A
    Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 14. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.
    Patel CB; De Lemos JA; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2006 Sep; 3(2):65-71. PubMed ID: 17058625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone: beyond glucose control.
    de Pablos-Velasco P
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1057-67. PubMed ID: 20670183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.